GlaxoSmithKline Pharmaceuticals
2,562.80
-25.10(-0.97%)
Market Cap₹43,415.38 Cr
PE Ratio45.94
IndustryHealthcare
Company Performance:
1D-0.97%
1M-7.39%
6M-5.83%
1Y+0.93%
5Y+81.30%
View Company Insightsright
More news about GlaxoSmithKline Pharmaceuticals
01Aug 25
GlaxoSmithKline Pharma Reports 12.6% Surge in Q1 Net Profit, EBITDA Margin Improves
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) reported strong Q1 financial results. Net profit rose 12.64% to Rs 205.00 crore from Rs 182.00 crore year-over-year. EBITDA increased to Rs 251.00 crore from Rs 231.00 crore, with EBITDA margin improving to 31.2% from 28.3%. Revenue slightly decreased by 0.76% to Rs 804.83 crore. Operating profit grew 14.15% to Rs 333.20 crore. Other income rose 15.95% to Rs 40.70 crore. The effective tax rate was 26.69%.
16May 25
GlaxoSmithKline Pharma Faces Production Setback Due to Fire at Contract Manufacturing Facility
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) reported a fire at one of its contract manufacturing facilities, causing temporary production disruption. The company is assessing the impact and working with site management to resume operations quickly. This incident could lead to short-term supply constraints, potential financial implications, and increased focus on disaster recovery plans. GSK Pharma is prioritizing the resumption of operations and will provide updates on the situation's development.
14May 25
GlaxoSmithKline Pharma Reports Strong Q4 Results, Announces Dividend
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) reported strong Q4 results with a 31.50% year-over-year increase in consolidated net profit to ₹2.63 billion. Revenue grew by 4.73% to ₹9.74 billion. The board recommended a final dividend of ₹42.00 per equity share. The company's performance shows significant growth in both revenue and profit, indicating effective cost management and operational efficiency in the Indian market.
13May 25
GlaxoSmithKline Pharma Reports Robust Q4 FY2025 Results, Announces ₹42 Dividend
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) announced impressive Q4 FY2025 results with revenue increasing to ₹966.00 crore, up 6.04% year-over-year. Full-year revenue for FY2025 reached ₹3,723.00 crore, a 9.00% increase from the previous year. The company plans to launch two oncology assets, Zejula and Jemperli, in FY2025-26. The board has recommended a final dividend of ₹42.00 per equity share.
18Feb 25
GlaxoSmithKline Pharmaceuticals Soars 17% on Stellar Q3 FY25 Performance
GlaxoSmithKline Pharmaceuticals' share price surged 17% following the release of its Q3 FY25 results. The company reported a 400% increase in consolidated net profit to ₹230 crore, an 18% rise in revenue to ₹949.42 crore, and an expanded EBITDA margin of 30.7%. The stock has rallied 36% over three days, reflecting strong investor confidence in the company's performance and growth prospects.
GlaxoSmithKline Pharmaceuticals
2,562.80
-25.10
(-0.97%)
1 Year Returns:+0.93%
Industry Peers
Sun Pharmaceutical
1,692.70
(+0.08%)
Divis Laboratories
6,686.00
(+0.44%)
Torrent Pharmaceuticals
3,777.00
(+5.50%)
Cipla
1,508.50
(+0.19%)
Dr Reddys Laboratories
1,199.60
(-0.48%)
Zydus Life Science
952.00
(+0.84%)
Mankind Pharma
2,238.00
(-1.05%)
Lupin
2,006.00
(+1.73%)
Alkem Laboratories
5,665.50
(-0.05%)
Aurobindo Pharma
1,138.10
(+1.27%)